Search Results

You are looking at 21 - 30 of 2,910 items for :

  • Refine by Access: All x
Clear All
Full access

Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy

Ashley E. Rosko, Sarah Wall, Robert Baiocchi, Don M. Benson, Jonathan E. Brammer, John C. Byrd, Yvonne A. Efebera, Kami Maddocks, Kerry A. Rogers, Desiree Jones, Lara Sucheston-Campbell, Hancong Tang, Hatice Gulcin Ozer, Ying Huang, Christin E. Burd, and Michelle J. Naughton

(mPhenoAge), has recently been reported, which is able to capture risk of adverse clinical outcomes across diverse tissue types 19 ; mPhenoAge has not yet been evaluated in a population with blood cancer. In this study, we explored mPhenoAge, markers of

Full access

Priority Rankings of Patient-Reported Outcomes for Pancreatic Ductal Adenocarcinoma: A Comparison of Patient and Physician Perspectives

Michelle Guan, Gillian Gresham, Arvind Shinde, Isaac Lapite, Jun Gong, Veronica R. Placencio-Hickok, Christopher B. Forrest, and Andrew E. Hendifar

goals to be adequately considered when treatment decisions are made. 5 Historically, priorities in oncology emphasized clinical outcomes and the evaluation of tumor response based on physician interpretation of parameters such as laboratory values, tumor

Full access

Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy

P. Connor Johnson, Caron Jacobson, Alisha Yi, Anna Saucier, Tejaswini M. Dhawale, Ashley Nelson, Mitchell W. Lavoie, Mathew J. Reynolds, Carlisle E.W. Topping, Matthew J. Frigault, and Areej El-Jawahri

, 5 , 11 However, data describing healthcare utilization and end-of-life (EoL) outcomes in this population are lacking. In the present study, we sought to describe the healthcare utilization and EoL outcomes among patients treated with CAR T

Full access

Association of Polypharmacy and Potentially Inappropriate Medications With Physical Functional Impairments in Older Adults With Cancer

Mostafa R. Mohamed, Erika Ramsdale, Kah Poh Loh, Huiwen Xu, Amita Patil, Nikesha Gilmore, Spencer Obrecht, Megan Wells, Ginah Nightingale, Katherine M. Juba, Bryan Faller, Adedayo Onitilo, Thomas Bradley, Eva Culakova, Holly Holmes, and Supriya G. Mohile

supportive care medications can increase the potential for clinically significant drug–drug interactions and adverse outcomes. 8 Polypharmacy is also associated with an increased risk of taking potentially inappropriate medications (PIMs; medications with a

Full access

Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

initiation of treatment with anti–PD-1 agents. Other than these few cases, there has been little published literature describing the endoscopic and histologic features of ICI-related esophagitis, treatment response, or clinical outcomes. There is a gap in

Full access

Oncologist Perceptions of Racial Disparity, Racial Anxiety, and Unconscious Bias in Clinical Interactions, Treatment, and Outcomes

Alexandrina Balanean, Emily Bland, Ajeet Gajra, Yolaine Jeune-Smith, Andrew J. Klink, Harlen Hays, and Bruce A. Feinberg

outcomes pervading the cancer journey are rooted in societal injustices, medical mistrust, systemic health care inequities, health illiteracy, and lack of access to quality care that adversely affect social determinants of health (SDoH) for racial or ethnic

Full access

Cancer Rehabilitation: Impact on Breast Cancer Survivors’ Work Ability and Health-Related Quality of Life

Mackenzi Pergolotti, Kelley C. Wood, Tiffany Kendig, Kim Love, and Stacye Mayo

. 9 Due to the high prevalence and negative sequelae associated with diminished work ability and HRQoL among BCSs, the ability to assess and provide appropriate interventions to optimize these outcomes is an urgent need in oncology care. 9 , 13 – 15

Full access

Trends in Outcomes of Patients With Metastatic Cancer Undergoing Intubation and Mechanical Ventilation: Results of the National Hospital Discharge Survey

Arjun Gupta, Avash Das, Raseen Tariq, Nizar Bhulani, Naveen Premnath, Dipesh Solanky, Ryan D. Frank, David Johnson, Sahil Khanna, and Muhammad S. Beg

questionable. Within the past few decades, ICU outcomes have improved drastically, owing to better management techniques, early identification of sicker patients, and more lenient admission criteria for ICUs. One recent study reported a 35% relative decrease

Full access

Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer

Jake S. Jacob, Barbara E. Dutra, Victor Garcia-Rodriguez, Kavea Panneerselvam, Fiyinfoluwa O. Abraham, Fangwen Zou, Weijie Ma, Petros Grivas, John A. Thompson, Mehmet Altan, Isabella C. Glitza Oliva, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang

and the ICI therapy course and lead to morbidity and mortality. Given the limited data on IMM, we evaluated the clinical characteristics, disease course, treatment, and outcome of IMM in patients at a tertiary cancer center. Methods Study

Full access

Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer

Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming

treatment with a non–EGFR-targeting regimen. We analyzed disease bulk as an independent predictor of clinical outcomes associated with anti-EGFR therapies to build on the impact of sidedness in the treatment-refractory setting. Using a single